Depression and health-care costs during the first year following myocardial infarction

N Frasure-Smith1, F Lespérance, G Gravel

  • 1Departments of Psychiatry, McGill University, Montreal, Quebec, Canada. frsm@icm.umontreal.ca

Insights

Depression after myocardial infarction (MI) significantly increases healthcare costs. Patients with elevated depression scores incurred 41% higher physician costs, mainly from outpatient visits and readmissions.

Area of Science:

  • Cardiology
  • Psychiatry
  • Health Economics

Background:

  • Post-myocardial infarction (MI) depression is linked to increased cardiac mortality.
  • Limited data exists on the economic impact of post-MI depression.

Purpose of the Study:

  • To investigate the association between post-MI depression and physician costs.
  • To analyze outpatient care and hospital readmission expenses in depressed MI survivors.

Main Methods:

  • Utilized Quebec Medicare data for 848 1-year survivors of acute MI.
  • Assessed depression using the Beck Depression Inventory (BDI) during hospitalization.
  • Compared healthcare costs between patients with BDI scores >=10 and those with normal scores.

Main Results:

  • Patients with elevated BDI scores had 41% higher total physician costs (p=0.004).
  • Increased costs were driven by outpatient visits, emergency room use, and longer hospital stays during readmissions.
  • Costs were not significantly influenced by psychiatric service utilization or revascularization readmissions.

Conclusions:

  • Post-MI depression is associated with substantial increases in healthcare costs beyond survival risks.
  • Readmissions and outpatient contacts contribute significantly to higher costs in depressed MI survivors.
  • The impact of increased healthcare utilization on depression and survival requires further investigation.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...